---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-24-001513"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:48:33.444334+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical reports 2023 net loss $26.2M; first FDA approval for Quelimmune pediatric device

## Summary
- Net loss $26.2M ($1.21/share) in 2023 vs $12.2M ($1.48/share) in 2022; cash $176K at Dec 31, 2023.
- FDA approved SCD-Pediatric (Quelimmune) in Feb 2024 for pediatric AKI with sepsis; distribution via Nuwellis.
- NEUTRALIZE-AKI adult trial enrolled 24 subjects; interim analysis expected H2 2024 after 100 reach 90-day endpoint.
- Appointed David A. Green as CFO in Jan 2024; completed $9.0M registered direct offering same month.
- Restated 2022 financials (non-cash items); minimal impact on cash/operations.

## SEC filing metadata
- accession: 0000929638-24-001513
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/0000929638-24-001513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-24-001513
- JSON: https://secwatch.observer/filing/0000929638-24-001513.json
- Plain text: https://secwatch.observer/filing/0000929638-24-001513.txt

## Key facts
- Earnings Releases
  SeaStar Medical Holding Corp reported financial results for the 12 months ended December 31, 2023.
  - Period: the 12 months ended December 31, 2023
  - Result: reported results
  source text: SeaStar Medical Reports 2023 Financial Results and Provides a Business Update DENVER (April 17, 2024) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/0000929638-24-001513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.